Objective: Lung cancer is one of the most common cancers in the world. It is known that angiogenesis plays a role in the development and metastasis of lung cancer. Azomethine derivatives known as Schiff bases have many biological activities. In this study, we aimed to determine the anticancer activity of the newly synthesized azomethine derivative compound B-47/2 on lung cancer and to determine the effect of this component on vascular endothelial growth factor B (VEGFB) gene expression.
Material and Method: Compound B-47/2 was synthesized for the first time. B-47/2 compound was applied to lung cancer cell line (A549) at varying concentrations (1-100 µg/mL) and its anticancer activity was found after 24, 48 and 72 hours incubations using the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) method. The half maximal inhibitory concentration (IC50) dose of B-47/2 was applied to the cells and ribonucleic acid (RNA) isolation followed by complementary deoxyribonucleic acid (cDNA) synthesis was performed. Then, reverse transcription-polymerase chain reaction (RT-PCR) method was used to determine the expression level of VEGFB gene.
Results: As a result, it was determined that the B-47/2 compound applied to the A-549 cell line showed the highest cytotoxic activity after 72 hours of incubation. In addition, it was determined that the B-47/2 compound decreased the expression of the VEGFB gene.
Discussion: There are studies in which the anticancer activity of azomethine derivatives has been observed. The topic of synthesizing new drugs to prevent cancer is popular. We suggested that the newly synthesized component may have anticancer activity and may be effective on angiogenesis.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Basic Science Research Articles |
Authors | |
Publication Date | December 31, 2022 |
Acceptance Date | December 19, 2022 |
Published in Issue | Year 2022 |